StockData
Spero Therapeutics, Inc. logo

Spero Therapeutics, Inc. (SPRO) stock

SPRONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 11/3045% below fair value
$0.90−0.05 (-4.77%)

Close on Nov 17, 2026Market cap $52.49MP/E 22.5Yield –

Spero Therapeutics pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

Spero Therapeutics's pe ratio was 25.5× on Nov 11, 2026, against 19.0× a year earlier.

PE Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 202625.5×+11.2
2025Jan 31, 202514.3×−2.9
2024Dec 31, 202417.2×–

More Spero Therapeutics figures

See a number that looks wrong?